These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23164313)

  • 1. Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker.
    Yano S; Moseley K; Azen C
    J Pediatr; 2013 May; 162(5):999-1003. PubMed ID: 23164313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation.
    Yano S; Moseley K; Azen C
    J Pediatr; 2014 Jul; 165(1):184-189.e1. PubMed ID: 24857519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Tetrahydrobiopterin Therapy with Large Neutral Amino Acid Supplementation in Phenylketonuria: Effects on Potential Peripheral Biomarkers, Melatonin and Dopamine, for Brain Monoamine Neurotransmitters.
    Yano S; Moseley K; Fu X; Azen C
    PLoS One; 2016; 11(8):e0160892. PubMed ID: 27513937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study.
    Schindeler S; Ghosh-Jerath S; Thompson S; Rocca A; Joy P; Kemp A; Rae C; Green K; Wilcken B; Christodoulou J
    Mol Genet Metab; 2007 May; 91(1):48-54. PubMed ID: 17368065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large Neutral Amino Acid Supplementation Exerts Its Effect through Three Synergistic Mechanisms: Proof of Principle in Phenylketonuria Mice.
    van Vliet D; Bruinenberg VM; Mazzola PN; van Faassen MH; de Blaauw P; Kema IP; Heiner-Fokkema MR; van Anholt RD; van der Zee EA; van Spronsen FJ
    PLoS One; 2015; 10(12):e0143833. PubMed ID: 26624009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic brain modulation with targeted large neutral amino acid supplements in the Pah-enu2 phenylketonuria mouse model.
    van Vliet D; Bruinenberg VM; Mazzola PN; van Faassen MH; de Blaauw P; Pascucci T; Puglisi-Allegra S; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
    Am J Clin Nutr; 2016 Nov; 104(5):1292-1300. PubMed ID: 27655443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future role of large neutral amino acids in transport of phenylalanine into the brain.
    Matalon R; Surendran S; Matalon KM; Tyring S; Quast M; Jinga W; Ezell E; Szucs S
    Pediatrics; 2003 Dec; 112(6 Pt 2):1570-4. PubMed ID: 14654667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Benefit of Large Neutral Amino Acid Supplementation to a Liberalized Phenylalanine-Restricted Diet in Adult Phenylketonuria Patients: Evidence from Adult
    van Vliet D; van der Goot E; van Ginkel WG; van Faassen MHJR; de Blaauw P; Kema IP; Martinez A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31546852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study.
    Burlina AP; Cazzorla C; Massa P; Polo G; Loro C; Gueraldi D; Burlina AB
    Nutrients; 2019 Oct; 11(10):. PubMed ID: 31640267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations.
    van Vliet D; van der Goot E; van Ginkel WG; van Faassen HJR; de Blaauw P; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
    Mol Genet Metab; 2022 Jan; 135(1):27-34. PubMed ID: 34974973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.
    Matalon R; Michals-Matalon K; Bhatia G; Burlina AB; Burlina AP; Braga C; Fiori L; Giovannini M; Grechanina E; Novikov P; Grady J; Tyring SK; Guttler F
    J Inherit Metab Dis; 2007 Apr; 30(2):153-8. PubMed ID: 17334706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large neutral amino acids in the treatment of PKU: from theory to practice.
    van Spronsen FJ; de Groot MJ; Hoeksma M; Reijngoud DJ; van Rijn M
    J Inherit Metab Dis; 2010 Dec; 33(6):671-6. PubMed ID: 20976625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults.
    Moats RA; Moseley KD; Koch R; Nelson M
    Pediatrics; 2003 Dec; 112(6 Pt 2):1575-9. PubMed ID: 14654668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is melatonin synthesis a new biomarker for the pathogenesis and treatment of phenylketonuria?
    Cederbaum S; Levy HL
    J Pediatr; 2013 May; 162(5):893-4. PubMed ID: 23312686
    [No Abstract]   [Full Text] [Related]  

  • 15. Large neutral amino acids in daily practice.
    Ahring KK
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S187-90. PubMed ID: 20300852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large neutral amino acids auto exchange when infused by microdialysis into the rat brain: implication for maple syrup urine disease and phenylketonuria.
    Zielke HR; Zielke CL; Baab PJ; Collins RM
    Neurochem Int; 2002 Apr; 40(4):347-54. PubMed ID: 11792465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomic changes demonstrate reduced bioavailability of tyrosine and altered metabolism of tryptophan via the kynurenine pathway with ingestion of medical foods in phenylketonuria.
    Ney DM; Murali SG; Stroup BM; Nair N; Sawin EA; Rohr F; Levy HL
    Mol Genet Metab; 2017 Jun; 121(2):96-103. PubMed ID: 28400091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying the effect of large neutral amino acid supplements on oxidative stress in phenylketonuric patients.
    Kumru B; Ozturk Hismi B; Kaplan DS; Celik H
    J Pediatr Endocrinol Metab; 2019 Mar; 32(3):269-274. PubMed ID: 30835252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.
    Scala I; Concolino D; Nastasi A; Esposito G; Crisci D; Sestito S; Ferraro S; Albano L; Ruoppolo M; Parenti G; Strisciuglio P
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).
    Harding CO; Winn SR; Gibson KM; Arning E; Bottiglieri T; Grompe M
    J Inherit Metab Dis; 2014 Sep; 37(5):735-43. PubMed ID: 24487571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.